
Merck KGaA to flog Allergopharma business to Dermapharm
pharmafile | February 21, 2020 | News story | Medical Communications, Sales and Marketing | Allergopharma, Dermapharm, Merck KGaA, pharma
German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of generics, dietary products, cosmetics and medical devices.
The business unit generated €88 million for Merck in 2018. It is currently developing a competitor to Mylan’s flagship EpiPen epinephrine autoinjector as a treatment for anaphylactic reactions.
The agreement includes Allergopharma’s therapeutic and diagnostic portfolio, but also its production site located in Reinbek, Germany.
The value of the sale was not disclosed, but Merck’s share price rose 1.34% on announcement of the news, while Dermapharm’s rose by 3.05%.
It was confirmed that the deal is expected to close in the second quarter of this year, subject to regulatory approval and satisfaction of closing conditions.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






